--- title: "Celcuity (CELC) news: offering and convertible notes" url: "https://aibio.space/companies/celcuity/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CELC offering and convertible notes news: Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan. Celcuity Inc." --- CELC Celcuity Inc. NASDAQ · United States # Celcuity (CELC) news CELC offering and convertible notes news Debt Financing · 2026-06-08 ## [Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan](https://aibio.space/news/celcuity-completes-575-000-000-convertible-notes-offering-repays/) Celcuity issued $575,000,000 of 0.250% convertible senior notes due 2032 on June 8, 2026, with net proceeds of approximately $557.0 million. It repaid its loan agreement in full the same day. ## Latest Celcuity news 1. 2026-06-03 Debt Financing [Celcuity prices upsized $500,000,000 convertible notes offering](https://aibio.space/news/celcuity-prices-upsized-500-000-000-convertible-notes-offering/) Celcuity priced $500,000,000 of 0.250% convertible senior notes due 2032, upsized from $400,000,000, with a 30-day option for $75,000,000 more. The company plans to use the proceeds first to repay its Oxford Finance loan. 2. 2026-06-03 Debt Financing [Celcuity proposes $400,000,000 convertible notes, then prices $500,000,000 at 0.250%](https://aibio.space/news/celcuity-proposes-400-000-000-convertible-notes-then-prices-500-000/) The notes mature on August 1, 2032, carry an initial conversion price of approximately $124.53 a share, and will repay the Oxford Finance and Innovatus loan in full. The last reported sale price on June 2, 2026 was $91.42. 3. 2025-09-10 Debt Financing [Celcuity upsizes term loan facility to $500 million with Innovatus and Oxford Finance](https://aibio.space/news/celcuity-upsizes-term-loan-facility-500-million-innovatus-oxford/) Celcuity drew $30 million at closing, bringing the term loan to $130 million. The $170 million of new committed capital depends on FDA approval of gedatolisib or on commercial revenue milestones. 4. 2025-08-01 Debt Financing [Celcuity completes $201,250,000 offering of 2.750% convertible senior notes due 2031](https://aibio.space/news/celcuity-completes-201-250-000-offering-2-750-percent-convertible/) Celcuity (Nasdaq: CELC) sold $201,250,000 of 2.750% convertible notes due 2031, including an over-allotment option the underwriters exercised on July 30, 2025. The notes convert at an initial price of about $51.30 per share, and the company sold stock and pre-funded warrants in a separate, concurrent offering. 5. 2024-12-06 Financings [Celcuity files for up to $125,000,000 of at-the-market stock sales](https://aibio.space/news/celcuity-files-up-125-000-000-market-stock-sales/) The supplement covers up to $125,000,000 of common stock sold through Jefferies LLC under a February 4, 2022 sales agreement. Shares with an aggregate offering price of up to $22,182,550 remained unsold under the 2022 supplement, and the filing gives a $12.71 last sale price on December 4, 2024. ## Celcuity at a glance - **Ticker**: CELC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $754.0 million ### Related companies - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) NASDAQ: RMTI - [Tectonic Therapeutic](https://aibio.space/companies/tectonic-therapeutic/) NASDAQ: TECX - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH - [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) AMEX: SER - [RenovoRx](https://aibio.space/companies/renovorx/) NASDAQ: RNXT - [Alpha Cognition](https://aibio.space/companies/alpha-cognition/) NASDAQ: ACOG - [Impact BioMedical](https://aibio.space/companies/impact-biomedical/) AMEX: IBO ### Also on NASDAQ - [Microbot Medical](https://aibio.space/companies/microbot-medical/) MBOT - [Zymeworks](https://aibio.space/companies/zymeworks/) ZYME - [X4 Pharmaceuticals](https://aibio.space/companies/x4-pharmaceuticals/) XFOR - [Bionano Genomics](https://aibio.space/companies/bionano-genomics/) BNGO - [iTonic Holdings](https://aibio.space/companies/itonic/) ITOC - [Veraxa Biotech](https://aibio.space/companies/veraxa-biotech/) VRXA ## What Celcuity does Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. Its lead candidate, gedatolisib, is a kinase inhibitor that binds all class I PI3K isoforms and the mTORC1 and mTORC2 complexes, inhibiting the PI3K/AKT/mTOR pathway. In the Phase 3 VIKTORIA-1 trial in hormone receptor-positive, HER2-negative advanced breast cancer, detailed results were reported for the PIK3CA wild-type cohort, and enrollment was completed in the PIK3CA mutant cohort. The Phase 3 VIKTORIA-2 trial evaluates gedatolisib with a CDK4/6 inhibitor and fulvestrant as first-line treatment and is ongoing. A Phase 1b/2 trial, CELC-G-201, is evaluating gedatolisib with darolutamide in metastatic castration resistant prostate cancer. Gedatolisib has Fast Track and Breakthrough Therapy designations for hormone receptor-positive advanced breast cancer after progression on CDK4/6 therapy. The FDA accepted the new drug application for gedatolisib on January 16, 2026, granting Priority Review under the Real-Time Oncology Review program, with a target user fee goal date of July 17, 2026. | Product or program | What it is | Stage | |---|---|---| | Gedatolisib | PI3K/AKT/mTOR pathway kinase inhibitor for hormone receptor-positive, HER2-negative advanced breast cancer | NDA accepted, Priority Review | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/form10-k.htm). ## Celcuity annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$145.0 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | [$104.2 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | | Net income (loss) | [-$177.0 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | [-$111.8 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | | Cash from operations | [-$153.3 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | [-$83.5 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | | Cash and equivalents | [$165.7 million](https://www.sec.gov/Archives/edgar/data/1603454/000119312526349608/) | [$22.5 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | | Short-term investments | [$275.8 million](https://www.sec.gov/Archives/edgar/data/1603454/000119312526349608/) | [$212.6 million](https://www.sec.gov/Archives/edgar/data/1603454/000149315226012801/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $182.0 million, plus short-term investments of $572.0 million, $754.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Celcuity Has Celcuity raised money recently? Our latest story on this, dated Jun 8, 2026: "Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/celcuity-completes-575-000-000-convertible-notes-offering-repays/). Has Celcuity sold convertible notes? Our latest story on this, dated Jun 8, 2026: "Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/celcuity-completes-575-000-000-convertible-notes-offering-repays/). What is the ticker symbol of Celcuity? Celcuity Inc. trades under the ticker CELC on NASDAQ. Where is Celcuity listed? Celcuity Inc. is listed on NASDAQ. What is the SEC CIK of Celcuity? The SEC Central Index Key (CIK) for Celcuity Inc. is 1603454. Its filings are on SEC EDGAR. How many shares does Celcuity have outstanding? 48,931,908 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Celcuity listed under? Our directory records Celcuity Inc. under United States. What does Celcuity do? Our directory classifies Celcuity Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Celcuity? The ISIN recorded for Celcuity Inc. is US15102K1007. Does aibio.space cover Celcuity? aibio.space lists Celcuity Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Celcuity incorporated? SEC records list its state or country of incorporation as DE. What does Celcuity develop? Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. Its lead candidate, gedatolisib, is a kinase inhibitor that binds all class I PI3K isoforms and the mTORC1 and mTORC2 complexes, inhibiting the PI3K/AKT/mTOR pathway. What is Gedatolisib from Celcuity? Gedatolisib: PI3K/AKT/mTOR pathway kinase inhibitor for hormone receptor-positive, HER2-negative advanced breast cancer Stage: NDA accepted, Priority Review. Is Celcuity profitable? Celcuity Inc. reported a net loss of $177.0 million for the fiscal year ended Dec 31, 2025, and used $153.3 million of cash in operations, per its annual report to the SEC. How much does Celcuity spend on research and development? $145.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Celcuity Members talk about Celcuity (CELC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Celcuity, newest first. Each line links the filing it comes from. 1. 2026-06-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1603454/000149315226026972/form424b5.htm) 2. 2026-01-09 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1603454/000149315226001112/forms-3asr.htm) 3. 2025-09-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1603454/000164117225027025/ex99-1.htm) 4. 2025-07-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1603454/000164117225021189/form424b5.htm) 5. 2024-12-06 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1603454/000149315224049068/form424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CELC on TradingView](https://www.tradingview.com/symbols/NASDAQ-CELC/). ## SEC filings and registration - **SEC name**: Celcuity Inc. - **CIK**: 1603454 - **Industry (SIC)**: Services-Medical Laboratories (8071) - **US tickers**: CELC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 16305 36TH AVENUE N, MINNEAPOLIS, MN, 55446 - **Phone**: 763-392-0767 - **Shares outstanding**: 48,931,908 as of 2026-08-05 (10-Q filed 2026-08-13) - **Former names**: Celcuity LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1603454/000119312526411297/celc-20261001.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1603454/000119312526408353/celc-20260930.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1603454/000119312526365975/celc-20260826.htm) filed 2026-08-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1603454/000119312526349608/celc-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1603454/000119312526349227/celc-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1603454/000149315226033223/form8-k.htm) filed 2026-07-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1603454/000149315226027717/form8-k.htm) filed 2026-06-08 - [424B5](https://www.sec.gov/Archives/edgar/data/1603454/000149315226027395/form424b5.htm) filed 2026-06-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001603454), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Celcuity Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CELC, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Celcuity Inc. - **Ticker**: CELC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US15102K1007 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CELC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/celcuity/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Celcuity (CELC) news: offering and convertible notes", 2026-10-31, https://aibio.space/companies/celcuity/